Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01386788
Other study ID # EML015722-600
Secondary ID 2009-010202-11
Status Recruiting
Phase N/A
First received June 27, 2011
Last updated June 30, 2011
Start date April 2009
Est. completion date February 2012

Study information

Verified date June 2011
Source Dr. Ernst MW Koch
Contact Ernst MW Koch, Dr.
Phone ++49 6257 1788
Email Ernst.MW.Koch@t-online.de
Is FDA regulated No
Health authority Germany: BfArM
Study type Observational

Clinical Trial Summary

Cyanide poisoning is commonly viewed as a rare but dramatic event, occurring in industrial or laboratory settings as the result of accidental releases of hydrogen cyanide (HCN) gas (e.g. in the case of fire) or salts in the case of suicide attempts.

In fact, cyanide poisoning is considerably more common than is generally appreciated. Multiple clinical and post-mortem studies have demonstrated that HCN contributes to the toxicity of fire smoke.

Cyanide acts primarily through its strong affinity for the iron-containing heme moiety, binding to numerous critical enzyme systems in the body and rendering them inactive. Of late, increasing attention has been paid to the relationship of cyanide and nitric oxide. The interactions appear to be complex, with cyanide inducing nitric oxide production by binding to N-methyl-D-aspartate (NMDA) receptors, as well as binding to nitric oxide synthase. The latter may be overcome by the presence of nitric oxide synthase inhibitors.

Probably, the majority of the cyanide poisoning cases are due to smoke inhalation in closed-space fires.

So far, there are no clear data available on the prevalence of cyanide poisoning in smoke inhalation.

This information would be of great interest for all emergency physicians since a proven or supposed cyanide poisoning does not only requires an intensive supportive care, including the administration of supplemental oxygen and artificial ventilation, blood pressure support, and anticonvulsants, but also a rapid administration of a cyanide antidote.

Therefore, it is the goal of this survey to assess the prevalence of cyanide poisoning in smoke inhalation victims. Only the data of patients with a cyanide measurement before specific antidote treatment will be included


Description:

Cyanide poisoning is commonly viewed as a rare but dramatic event, occurring in industrial or laboratory settings as the result of accidental releases of hydrogen cyanide (HCN) gas (e.g. in the case of fire) or salts in the case of suicide attempts.

In fact, cyanide poisoning is considerably more common than is generally appreciated. Multiple clinical [1-4] and post-mortem studies [5-10] have demonstrated that HCN contributes to the toxicity of fire smoke.

Cyanide acts primarily through its strong affinity for the iron-containing heme moiety, binding to numerous critical enzyme systems in the body and rendering them inactive [11]. Of late, increasing attention has been paid to the relationship of cyanide and nitric oxide. The interactions appear to be complex, with cyanide inducing nitric oxide production by binding to N-methyl-D-aspartate (NMDA) receptors [12], as well as binding to nitric oxide synthase. The latter may be overcome by the presence of nitric oxide synthase inhibitors.

Probably, the majority of the cyanide poisoning cases are due to smoke inhalation in closed-space fires.

So far, there are no clear data available on the prevalence of cyanide poisoning in smoke inhalation.

This information would be of great interest for all emergency physicians since a proven or supposed cyanide poisoning does not only requires an intensive supportive care, including the administration of supplemental oxygen and artificial ventilation, blood pressure support, and anticonvulsants, but also a rapid administration of a cyanide antidote.

Therefore, it is the goal of this survey to assess the prevalence of cyanide poisoning in smoke inhalation victims. Only the data of patients with a cyanide measurement before specific antidote treatment will be included.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date February 2012
Est. primary completion date December 2011
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Closed space fire, Soot deposits, Altered mental status

- Blood specimen before intravenous antidote treatment (cyanide measurement)

- Known delay between end of smoke exposure and blood sampling

- Malaise and/or Headache and/or Altered mental status in fireworkers

Exclusion Criteria:

- Pregnancy

- Multiple trauma, Blast

- Patient pronounced dead at scene without resuscitation attempt

- Patient in whom the time elapsed between the end of exposure and blood sampling is greater than 2 hours

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Intervention

Other:
There is no intervention planned (observational)
No intervention foreseen

Locations

Country Name City State
Germany Prof. Dr. Götz Geldner Ludwigsburg
Germany Prof. Th. Zilker München

Sponsors (1)

Lead Sponsor Collaborator
Dr. Ernst MW Koch

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Survival participants will be followed for the duration of hospital stay, an expected average of 30 days No
See also
  Status Clinical Trial Phase
Completed NCT03558646 - Impact of Hydroxocobalamine on Outcome of Smoke Inhalation Injury Admitted to the ICU